Renal and vascular consequences of the chronic nitric oxide synthase inhibition: Effects of antihypertensive drugs

American Journal of Hypertension

Volumn 9, Issue 11, 1996, Pages 1077-1083

  Navarro Cid, Josefa ^a   Maeso, Rosaura ^a   Rodrigo, Elena ^a   Muñoz García, Raquel ^a   Ruilope, Luis M ^b   Lahera, Vicente ^a   Cachofeiro, Victoria ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium antagonists; Hypertension; Nitric oxide; Proteinuria; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; CREATININE; DILTIAZEM; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENZYME INHIBITION; HYPERTENSION; KIDNEY FUNCTION; MALE; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ISOQUINOLINES; KIDNEY; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION; TETRAHYDROISOQUINOLINES;

EID: 0029804006     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00195-1     Document Type: Article

References (38)

1. Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
2. Rees DD, Palmer RJM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
3. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991;261:F1033-F1037.
4. Navarro J, Sanchez A, Saiz J, et al: Hormonal, renal, and metabolic alterations during hypertension induced by chronic inhibition of NO in rats. Am J Physiol 1994; 267:R1516-R1521.
5. Oliveira M, Antunes E, de Nucci G, et al: Chronic inhibition of nitric oxide synthesis. A new model of hypertension. Hypertension 1992;20:298-303.
6. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ: Atigiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 1993;21:660-666.
7. Fujihara CK, Michellazo SM, de Nucci G, Zats R: Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994;266:F697-F705.
8. Okamura M, Konishi Y, Nishimura M, et al: Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist. Blood Pressure 1994;3(suppl 5):75-78.
9. G-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin. J Pharmacol Exp Ther 1992;261:240-245.
10. Takase H, Moreau P, Küng CF, et al: Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996;27:25-31.
11. Gansevoort RT, de Zeeuw DD, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
12. Panza JA, Casino PR, Kilcoyne RN, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-1474.
13. G-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994;12:1047-1052.
14. Jover B, Herizi A, Ventre F, et al: Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993;21:944-948.
15. Iwata J, Nishikaze O: New micro-turbidimetric method for determination of protein in cerebrospinal fluid and urine. Clin Chem 1979;25:1317-1319.
16. Manning RD, Jr, Hu L, Mizelle HL, et al: Cardiovascular responses to long-term blockade of nitric oxide synthesis. Hypertension 1993;22:40-48.
17. Gruetter CA, Ryan ET, Lemke SM, et al: Endothelium-dependent modulation of angiotension II-induced contraction in blood vessels. Eur J Pharmacol 1988;146:85-95.
18. Sigmon DH, Carretero OA, Beierwaltes WH: Angiotensin dependence of endothelium-mediated renal hemodynamics. Hypertension 1992;20:643-650.
19. Ito S, Johnson CS, Carretero OA: Modulation of angiotensin II vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1991;87:1656-1663.
20. G-Monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol 1992;262:R1137-R1144.
21. Bank N, Aynedjian HS, Khan GA: Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension 1994;24:322-328.
22. Lockette A, Otsuka Y, Carretero O: The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension 1986;8(suppl II):II-61-66.
23. Tesfamariam B, Halpern W: Endothelium-dependent and endothelium-independent vasodilation in resistance arteries from hypertensive rats. Hypertension 1988;11:440-444.
24. Lüscher TF, Diederich D, Weber E, et al: Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. Hypertension 1988;11:573-578.
25. Dohi Y, Thiel M, Bühler FR, Lüscher TF: Activation of the endothelial L-arginine pathway in pressurized mesenteric resistance arteries: effect of age and hypertension. Hypertension 1990;15:170-179.
26. Feletou M, Vanhoutte PM: Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-524.
27. Furchgott RF, Vanhoutte PM: Endothelium-derived relaxing factor and contracting factor. FASEB J 1989; 3:2007-2018.
28. Mitchell JA, de Nucci G, Warner T, Vane JR: Different pattern of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol 1992;105:485-489.
29. Parsons SJW, Hill A, Waldron GJ, et al: The relative importance of nitric oxide and nitric oxide-independent mechanisms in acetylcholine-evoked dilatation of the rat mesenteric bed. Br J Pharmacol 1994;113:1275-1280.
30. Qiu HY, Henrion D, Levy BI: Endogenous angiotensin II enhances phenylephrine induced tone in hypertensive rats. Hypertension 1994;24:317-321.
31. Kadekaro M, Terrell ML, Harmann P, Summy-Long JY: Central inhibition of nitric oxide synthase attenuates water intake but does not alter enhanced glucose utilization in the hypothalamo-neurohypophysis system of dehydrated rats. Neurosci Lett 1994;173:115-118.
32. Raber J, Bloom FE: IL-2 induces vasopressin release from the hypothalamus and the amygdala: role of nitric oxide-mediated signalling. J Neurosci 1994;14:6187-6195.
33. Kassirer JP, Harrington JT: Laboratory evaluation on renal function, in Schrier RW, Gottschalk CW (eds.): Diseases of the Kidney. Little, Brown and Co., Boston, 1988, pp 393-441.
34. Kaysen GA, Myers BD, Couser WG: Mechanisms and consequences of proteinuria. Lab Invest 1986;54:479-484.
35. Ruilope LM, Rodicio JL: Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993;2:962-967.
36. Beretta-Picoli C: Diabetes mellitus and hypertension, in Robertson JIS (ed): Handbook of Hypertension, Vol. 11: Clinical Hypertension. Amsterdam, Elsevier, 1992, pp 141-176.
37. Zanetti-Elshater F, Pingitore R, Beretta-Piccoli C, et al: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens 1994;7:36-45.
38. Romero JC, Ruilope LM, Bentley MD, et al: Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am J Cardiol 1988;62:59G-68G.